Vivodyne's AI platform is transforming drug development by testing on lab-grown human organs.
Vivodyne, a biotech research startup, has announced $38 million in funding led by Khosla Ventures. Vivodyne leverages AI-scale testing on lab-grown human organs for preclinical testing for every stage of drug development.
Vivodyne enables their biopharma partners to see human data even before clinical trials and reduces the need for animal testing. Their platform can mimic drug interactions with human cells offering more precise results, enhance drug success rates and accelerate the discovery of more effective treatments.
“We’re thrilled to have Khosla Ventures lead this funding round, which accelerates the development of our AI platform that enables the generation of predictive human data before therapeutics enter clinical trials,” said Andrei Georgescu, CEO and Co-Founder of Vivodyne.
Vivodyne plans to expand its platform and potentially collaborate with top biopharma companies. This expansion aims to advance AI-driven drug discovery using its extensive human data sets.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/38m-funding-for-ai-driven-biotech-startup-led-by-khosla-ventures"
},
"headline": "$38M Funding for AI Driven Biotech Startup led by Khosla Ventures",
"description": "Vivodyne's AI platform is transforming drug development by testing on lab-grown human organs.",
"image": "",
"author": {
"@type": "",
"name": ""
},
"publisher": {
"@type": "Organization",
"name": "The Money Game",
"logo": {
"@type": "ImageObject",
"url": "https://www.themoney.game"
}
},
"datePublished": "2023-11-27"
}
</script>